Upcoming Webinars
SPEAKER/S: Professor Jean-Paul Desaulniers
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Dr. Eliot Morrison, Silence Therapeutics
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Tiberiu Stan, PhD, Štefan Moravčík, PharmD.
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Aurélie Goyenvalle, PhD
TIME: 8am PDT / 11am EDT / 5pm CEST
Recent Webinars
Past Webinars
Making medicines out of pre-mRNA splicing modulators
Presenter: Isabel Aznarez, Ph.D. Stoke Therapeutics Date: April 29th, 2021 Description: Splicing is the process that edits precursor-messenger RNA (pre-mRNA) to generate the messenger RNA (mRNA) that carries the code from the nucleus to the cytoplasm where the ribosomes will translate it into a protein. The splicing reaction is ...
The N-Lorem Foundation
Presenter: Stanley T. Crooke, MD, PhD Ionis Pharmaceuticals Date: February 9th, 2021 Description: The purpose of this presentation is to formally introduce n-Lorem to OTS and to summarize progress since being founded in January 2020. Recording of the webinar: Click play to view ...
Academia or Industry? A career discussion
Presenter: Prof. Annemieke Aartsma-Rus, (OTS President; Leiden University Medical Center) and Dr. Shalini Andersson (Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca) Date: July 15, 2020 Description: To start off, Prof. Annemieke Aartsma-Rus (OTS President; Leiden University Medical Center) and Dr. Shalini Andersson (Chief Scientist New ...
Time matters! – Why PK/PD is important for oligo development
Presenter: Carl Amilon (AstraZeneca) Date: June 10, 2020 Description: This webinar will give an overview of how incorporating quantitative PK/PD aspects of an oligonucleotide will help you designing more informative experiments and help in translating to a human. We have all struggled with questions around the expectations of a study outcome ...
Safety of Therapeutic Oligonucleotides
Presenter: Patrik Andersson (AstraZeneca) Date: May 13, 2020 Description: Successful therapeutics need to be efficacious and safe. Although oligonucleotide therapeutics act via unique mechanisms, they follow the same principles for safety assessment as other modalities. This webinar will give an overview of these principles and what needs to be considered from ...
Delivery of Macromolecular Therapeutics: Tackling a Billion Year Old Barrier
Presenter: Steven Dowdy (UCSD School of Medicine) Date: December 17, 2019 Description: All macromolecular therapeutics, including ASOs, siRNAs, peptides, proteins, CRISPR, mRNA and non-viral DNA vectors, are taken up into cells by endocytosis. However, <1% to none of the endocytosed therapeutic cargo escapes into the cytoplasm and nucleus of the cell. ...
Making medicines out of pre-mRNA splicing modulators
Presenter: Isabel Aznarez, Ph.D. Stoke Therapeutics Date: April 29th, 2021 Description: Splicing is the process that edits precursor-messenger RNA ...
The N-Lorem Foundation
Presenter: Stanley T. Crooke, MD, PhD Ionis Pharmaceuticals Date: February 9th, 2021 Description: The purpose of this presentation is to formally introduce ...
Academia or Industry? A career discussion
Presenter: Prof. Annemieke Aartsma-Rus, (OTS President; Leiden University Medical Center) and Dr. Shalini Andersson (Chief Scientist New Therapeutic Modalities ...
Time matters! – Why PK/PD is important for oligo development
Presenter: Carl Amilon (AstraZeneca) Date: June 10, 2020 Description: This webinar will give an overview of how incorporating quantitative PK/PD aspects ...
Safety of Therapeutic Oligonucleotides
Presenter: Patrik Andersson (AstraZeneca) Date: May 13, 2020 Description: Successful therapeutics need to be efficacious and safe. Although oligonucleotide therapeutics act ...
Delivery of Macromolecular Therapeutics: Tackling a Billion Year Old Barrier
Presenter: Steven Dowdy (UCSD School of Medicine) Date: December 17, 2019 Description: All macromolecular therapeutics, including ASOs, siRNAs, peptides, proteins, CRISPR, ...
